Ligand Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Ligand Pharmaceuticals has a total shareholder equity of $806.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $913.9M and $107.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$310.59m |
Equity | US$806.52m |
Total liabilities | US$107.35m |
Total assets | US$913.87m |
Recent financial health updates
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?
Dec 03Recent updates
Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
Apr 30Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Ligand Pharmaceuticals: Moving Parts Keep Moving
Mar 29We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New Year
Dec 31Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?
Dec 03Financial Position Analysis
Short Term Liabilities: LGND's short term assets ($368.9M) exceed its short term liabilities ($17.8M).
Long Term Liabilities: LGND's short term assets ($368.9M) exceed its long term liabilities ($89.5M).
Debt to Equity History and Analysis
Debt Level: LGND is debt free.
Reducing Debt: LGND has no debt compared to 5 years ago when its debt to equity ratio was 59.6%.
Debt Coverage: LGND has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: LGND has no debt, therefore coverage of interest payments is not a concern.